{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T21:07:35Z","timestamp":1774645655781,"version":"3.50.1"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"11-12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Anxiety disorders are among the most commonly diagnosed of psychiatric disorders. Many symptoms of posttraumatic stress disorder are also anxiety-related. Traditional medications used to treat these disorders, such as antidepressants and benzodiazepines, are often ineffective, not well-tolerated, and can be habit forming. An alternative agent is, therefore, needed. Beta-blockers are one class of medication with potential to treat anxiety-related disorders; however, current evidence remains limited and requires further characterization. To this end, this retrospective study aims to present a novel preliminary report on the use of the beta-blocker, atenolol, to potentially treat anxiety-related disorders.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and methods<\/jats:title>\n                  <jats:p>Ninety-two patients were identified from outpatient military mental health clinics in Okinawa, Japan, who had received atenolol for mental health-related symptoms. Primary measures collected were the rates of patient-reported (1) general beneficial\/positive effect of atenolol, (2) adverse effects from atenolol, and (3) preference of atenolol to propranolol. Data were collected from patients who were given binary response options to report their perceived experiences for each primary measure. This study was approved by the Naval Medical Center San Diego Institutional Review Board.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The results showed 86% of patients reporting a positive effect and continuing to take atenolol, including 87% with a diagnosis of posttraumatic stress disorder, 100% with diagnosis of other specified trauma- and stressor-related disorder, and 81% diagnosed with anxiety disorders. In total, 90% of patients denied adverse effects or found the adverse effects tolerable. Additionally, 100% of patients who had previously taken propranolol for anxiety reported that they preferred atenolol.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The present preliminary observational data suggests that atenolol may be well-tolerated and effective among persons with anxiety disorders. These data also suggest that atenolol may be more effective and better tolerated than propranolol, which is the most commonly prescribed beta-blocker for these conditions; however, more rigorously controlled empirical studies are needed to further substantiate this claim. Despite an overwhelmingly high rate of positive reports from patients\u2019 self-evaluations of atenolol treatment for anxiety-related disorders, this early investigation was not placebo-controlled nor double-blinded, and formal outcome measures were not assessed due to a lack of availability. More detailed examinations are needed to further determine whether atenolol is a viable alternative or augmenting agent to propranolol, benzodiazepines, and antidepressants for anxiety disorders and trauma-related disorders.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/milmed\/usaa170","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T07:28:18Z","timestamp":1596094098000},"page":"e1954-e1960","source":"Crossref","is-referenced-by-count":22,"title":["A Preliminary Investigation on the Effects of Atenolol for Treating Symptoms of Anxiety"],"prefix":"10.1093","volume":"185","author":[{"given":"Cody","family":"Armstrong","sequence":"first","affiliation":[{"name":"3d Medical Battalion, Unit 38445; FPO, AP 96373-8445, Okinawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle R","family":"Kapolowicz","sequence":"additional","affiliation":[{"name":"School of Medicine, Department of Otolaryngology \u2013 Head and Neck Surgery, University of California, Irvine, CA, 92697, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,12,30]]},"reference":[{"key":"2020123002501281300_ref1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.31887\/DCNS.2015.17.3\/bbandelow","article-title":"Epidemiology of anxiety disorders in the 21st century","volume":"17","author":"Bandelow","year":"2015","journal-title":"Dialogues Clin Neurosci"},{"key":"2020123002501281300_ref2","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","edition":"5th"},{"key":"2020123002501281300_ref3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","article-title":"Treatment of anxiety disorders","volume":"19","author":"Bandelow","year":"2017","journal-title":"Dialogues Clin Neurosci"},{"key":"2020123002501281300_ref4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0165-0327(87)90017-6","article-title":"Beta-blockers in anxiety disorders","volume":"13","author":"Hayes","year":"1987","journal-title":"J Affect Disord"},{"issue":"2","key":"2020123002501281300_ref5","doi-asserted-by":"crossref","DOI":"10.29046\/JJP.009.2.002","article-title":"The management of performance anxiety with beta-adrenergic blocking agents","volume":"9","author":"Bourgeois","year":"1991","journal-title":"Jefferson J Psychiatry"},{"issue":"2","key":"2020123002501281300_ref6","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1177\/0269881115612236","article-title":"Propranolol for the treatment of anxiety disorders: systematic review and meta-analysis","volume":"30","author":"Steenen","year":"2016","journal-title":"J Psychopharmacol"},{"issue":"2","key":"2020123002501281300_ref7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF03188723","article-title":"Clinical pharmacokinetics of atenolol \u2013 a review","volume":"7","author":"Kirch","year":"1982","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"2020123002501281300_ref8","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1016\/S0140-6736(04)17355-8","article-title":"Atenolol in hypertension: is it a wise choice?","volume":"364","author":"Carlberg","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"2020123002501281300_ref9","doi-asserted-by":"crossref","first-page":"204","DOI":"10.4330\/wjc.v7.i4.204","article-title":"Autonomic and endocrine control of cardiovascular function","volume":"7","author":"Gordan","year":"2015","journal-title":"World J Cardiol"},{"key":"2020123002501281300_ref10","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00004714-199112000-00003","article-title":"A controlled study of alprazolam and propranolol in panic-disordered and agoraphobic outpatients","volume":"11","author":"Ravaris","year":"1991","journal-title":"J Clin Psychopharmacol"},{"key":"2020123002501281300_ref11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1365-2125.1974.tb00274.x","article-title":"Physiological response to propranolol and diazepam in chronic anxiety","volume":"1","author":"Tyrer","year":"1974","journal-title":"Br J Clin Pharmacol"},{"key":"2020123002501281300_ref12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1136\/bmj.2.5909.14","article-title":"Response to propranolol and diazepam in somatic and psychic anxiety","volume":"2","author":"Tyrer","year":"1974","journal-title":"Br Med J"},{"key":"2020123002501281300_ref13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/0002-9343(82)90592-7","article-title":"Effect of beta blockade and beta stimulation on stage fright","volume":"72","author":"Brantigan","year":"1982","journal-title":"Am J Med"},{"key":"2020123002501281300_ref14","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1365-2125.1985.tb02714.x","article-title":"The effect of acute betaadrenoceptor blockade on examination performance","volume":"19","author":"Drew","year":"1985","journal-title":"Br J Clin Pharmacol"},{"key":"2020123002501281300_ref15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1177\/000992289103000706","article-title":"The effect of beta blockade on stress-induced cognitive dysfunction in adolescents","volume":"30","author":"Faigel","year":"1991","journal-title":"Clin Pediatr"},{"key":"2020123002501281300_ref16","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0006-3223(01)01279-3","article-title":"Pilot study of secondary prevention of posttraumatic stress disorder with propranolol","volume":"51","author":"Pitman","year":"2002","journal-title":"Biol Psychiatry"},{"key":"2020123002501281300_ref17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0006-3223(03)00412-8","article-title":"Immediate treatment with propranolol decreases posttraumatic stress disorder two months after trauma","volume":"54","author":"Vaiva","year":"2003","journal-title":"Biol Psychiatry"},{"key":"2020123002501281300_ref18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1755-5949.2010.00227.x","article-title":"Effect of acute posttrauma propranolol on PTSD outcome and physiological responses during script-driven imagery","volume":"18","author":"Hoge","year":"2012","journal-title":"CNS Neurosci Ther"},{"key":"2020123002501281300_ref19","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1136\/jme.2008.024752","article-title":"Post-traumatic stress disorder and narrative identity","volume":"34","author":"Propranolol","year":"2008","journal-title":"J Med Ethics"},{"key":"2020123002501281300_ref20","first-page":"34","article-title":"Posttraumatic stress disorder and acute stress disorder II: considerations for treatment and prevention","volume":"2","author":"Cahill","year":"2005","journal-title":"Psychiatry"},{"key":"2020123002501281300_ref21","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1176\/jnp.11.3.328","article-title":"Propranolol treatment of chronically hospitalized aggressive patients","volume":"11","author":"Silver","year":"1999","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"2020123002501281300_ref22","first-page":"213","article-title":"Beta-adrenoceptor antagonists in neuropsychiatry: an update","volume":"49","author":"Lader","year":"1988","journal-title":"J Clin Psychiatry"},{"key":"2020123002501281300_ref23","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/00006842-198211000-00008","article-title":"Stage fright in musicians: a model illustrating the effect of beta blockers","volume":"44","author":"Neftel","year":"1982","journal-title":"Psychosom Med"},{"key":"2020123002501281300_ref24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJM198510103131501","article-title":"Randomized clinical trial of atenolol in patients with alcohol withdrawal","volume":"313","author":"Kraus","year":"1985","journal-title":"N Engl J Med"},{"key":"2020123002501281300_ref25","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archinte.1989.00390050075015","article-title":"The efficacy of atenolol in the outpatient management of the alcohol withdrawal syndrome. Results of a randomized clinical trial","volume":"149","author":"Horwitz","year":"1989","journal-title":"Arch Intern Med"},{"key":"2020123002501281300_ref26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0740-5472(94)90083-3","article-title":"Randomized controlled trial in alcohol relapse prevention: role of atenolol, alcohol craving, and treatment adherence","volume":"11","author":"Gottlieb","year":"1994","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"2020123002501281300_ref27","first-page":"303","article-title":"Treatment of anxiety prior to a medical procedure using an atenolol - scopolamine combination drug","volume":"7","author":"Thomas","year":"2018","journal-title":"J Depress Anxiety"},{"issue":"2","key":"2020123002501281300_ref28","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.26420\/anndepressanxiety.2017.1086","article-title":"Atenolol - scopolamine combination drug decreases acute anxiety post trauma therapy session","volume":"4","author":"Benjamin","year":"2017","journal-title":"Ann Depress Anxiety"},{"issue":"12","key":"2020123002501281300_ref29","first-page":"e1","article-title":"A compounded, nonbenzodiazepine option for treating acute anxiety","volume":"16","author":"Benjamin","year":"2017","journal-title":"Curr Psychiatr Ther"},{"issue":"2","key":"2020123002501281300_ref30","first-page":"1088","article-title":"Treatment of acute anxiety episodes in patients using a fast-acting beta blocker \u2013 scopolamine combination drug","volume":"4","author":"Thomas","year":"2017","journal-title":"Ann Depress Anxiety"},{"issue":"3","key":"2020123002501281300_ref31","first-page":"1","article-title":"Beta blocker - scopolamine combination drug decreases acute anxiety in a PTSD patient \u2013 a case report","volume":"2","author":"Benjamin","year":"2017","journal-title":"ARC J Psychiatry"},{"issue":"5","key":"2020123002501281300_ref32","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.cjca.2013.12.001","article-title":"Contemporary use of \u03b2-blockers: clinical relevance of subclassification","volume":"30","author":"Poirier","year":"2014","journal-title":"Can J Cardiol"},{"key":"2020123002501281300_ref33","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.bjp.0706048","article-title":"The selectivity of \u03b2-adrenoceptor antagonists at the human \u03b21, \u03b22 and \u03b23 adrenoceptors","volume":"144","author":"Baker","year":"2005","journal-title":"Br J Pharmacol"},{"issue":"6","key":"2020123002501281300_ref34","first-page":"843","article-title":"The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers","volume":"34","author":"Pauwels","year":"1988","journal-title":"Mol Pharmacol"},{"issue":"551","key":"2020123002501281300_ref35","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3399\/bjgp08X299317","article-title":"Changing beta-blockers in heart failure: when is a class not a class?","volume":"58","author":"Aronson","year":"2008","journal-title":"Br J Gen Pract"},{"issue":"4","key":"2020123002501281300_ref36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1159\/000093060","article-title":"Comparing beta-blocking effects of bisoprolol, carvedilol and nebivolol","volume":"106","author":"Stoschitzky","year":"2006","journal-title":"Cardiology"},{"issue":"2","key":"2020123002501281300_ref37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1023\/B:CARD.0000029031.87129.05","article-title":"Different effects of exercise on plasma concentrations of nebivolol, bisoprolol and carvedilol","volume":"18","author":"Stoschitzky","year":"2004","journal-title":"Cardiovasc Drugs Ther"},{"key":"2020123002501281300_ref38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0009-2797(96)03726-X","article-title":"Cytochrome P450 enzymes involved in the enhancement of propranolol N-desisopropylation after repeated administration of propranolol in rats","volume":"101","author":"Narimatsu","year":"1996","journal-title":"Chem Biol Interact"},{"key":"2020123002501281300_ref39","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/archinte.162.4.405","article-title":"Implications of cytochrome P450 interactions when prescribing medication for hypertension","volume":"162","author":"Flockhart","year":"2002","journal-title":"Arch Intern Med"},{"key":"2020123002501281300_ref40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40779-015-0053-2","article-title":"Primary prevention of posttraumatic stress disorder: drugs and implications","volume":"2","author":"Burbiel","year":"2015","journal-title":"Milit Med Res"},{"key":"2020123002501281300_ref41","author":"Rehman","year":"2020"},{"issue":"Suppl","key":"2020123002501281300_ref42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00543713","article-title":"CNS-related side effects with metoprolol and atenolol","volume":"28","author":"Cove-Smith","year":"1985","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"2020123002501281300_ref43","doi-asserted-by":"crossref","first-page":"271","DOI":"10.31887\/DCNS.2002.4.3\/gcassano","article-title":"Psychopharmacology of anxiety disorders","volume":"4","author":"Cassano","year":"2002","journal-title":"Dialogues Clin Neurosci"}],"container-title":["Military Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/185\/11-12\/e1954\/35269007\/usaa170.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/milmed\/article-pdf\/185\/11-12\/e1954\/35269007\/usaa170.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,30]],"date-time":"2020-12-30T07:52:34Z","timestamp":1609314754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/milmed\/article\/185\/11-12\/e1954\/5874725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,1]]},"references-count":43,"journal-issue":{"issue":"11-12","published-online":{"date-parts":[[2020,12,30]]},"published-print":{"date-parts":[[2020,12,30]]}},"URL":"https:\/\/doi.org\/10.1093\/milmed\/usaa170","relation":{},"ISSN":["0026-4075","1930-613X"],"issn-type":[{"value":"0026-4075","type":"print"},{"value":"1930-613X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,11,1]]},"published":{"date-parts":[[2020,11,1]]}}}